Recent Advances in the Clinical Value and Potential of Dexmedetomidine

Abstract

Dexmedetomidine, a highly selective α2-adrenoceptor agonist, has sedative, anxiolytic, analgesic, sympatholytic, and opioid-sparing properties and induces a unique sedative response which shows an easy transition from sleep to wakefulness, thus allowing a patient to be cooperative and communicative when stimulated. Recent studies indicate several emerging clinical applications via different routes. We review recent data on dexmedetomidine studies, particularly exploring the varying routes of administration, experimental implications, clinical effects, and comparative advantages over other drugs. A search was conducted on the PubMed and Web of Science libraries for recent studies using different combinations of the words “dexmedetomidine”, “route of administration”, and pharmacological effect. The current routes, pharmacological effects, and application categories of dexmedetomidine are presented. It functions by stimulating pre- and post-synaptic α2-adrenoreceptors within the central nervous system, leading to hyperpolarization of noradrenergic neurons, induction of an inhibitory feedback loop, and reduction of norepinephrine secretion, causing a sympatholytic effect, in addition to its anti-inflammation, sleep induction, bowel recovery, and sore throat reduction effects. Compared with similar α2-adrenoceptor agonists, dexmedetomidine has both pharmacodynamics advantage of a significantly greater α2:α1-adrenoceptor affinity ratio and a pharmacokinetic advantage of having a significantly shorter elimination half-life. In its clinical application, dexmedetomidine has been reported to present a significant number of benefits including safe sedation for various surgical interventions, improvement of intraoperative and postoperative analgesia, sedation for compromised airways without respiratory depression, nephroprotection and stability of hypotensive hemodynamics, reduction of postoperative nausea and vomiting and postoperative shivering incidence, and decrease of intraoperative blood loss. Although the clinical application of dexmedetomidine is promising, it is still limited and further research is required to enhance understanding of its pharmacological properties, patient selection, dosage, and adverse effects.

Introduction

Dexmedetomidine is an anxiolytic, sedative, and pain medication. It is notable for its ability to provide sedation without risk of respiratory depression as compared to other commonly used drugs such as fentanyl and propofol and can provide cooperative or semi-rousable sedation. As a sympatholytic drug, dexmedetomidine functions as an agonist of α2-adrenergic receptors in certain parts of the brain.^1,2 Although it was initially approved for intravenous use for up to 24 hours in the adult intensive care unit population only, its applications in clinical practice have been broadened over the past few years. Procedural sedation with dexmedetomidine was additionally approved by the US Food and Drug Administration in 2003 and it has appeared useful in multiple off-label applications including pediatric sedation, oral or intranasal administration, and use as an adjuvant to local analgesia/anesthetic techniques.^3–7 Dexmedetomidine can reduce postoperative delirium incidence, a relatively common and serious complication in surgical patients where there is a temporary mental state characterized by confusion, incoherent speech, anxiety, and hallucinations.^8,9

The many favorable physiological effects of dexmedetomidine have resulted in its increasing popularity and application, generating a lot of preclinical and clinical studies over the past few years. These studies have featured its administration through several routes including intravenous, intrathecal, intranasal, intramuscular, inhalational, and oral, as well as in procedural and surgical sedations. Considering the progressive and dynamic nature of research, constantly examining updates and advances made in an important field such as dexmedetomidine application is of high importance, especially, a well-integrated overview that captures latest data on the subject. This paper examines current data on both experimental and clinical values of dexmedetomidine, and in relation to comparative studies with similar agents. Using different combinations of the words “dexmedetomidine”, “route of administration”, “application”, and pharmacological effect, a search was conducted on the PubMed and Web of Science libraries for recent studies, particularly, within the past five years.

Overview of Dexmedetomidine

As a highly selective a2 adrenergic receptor agonist, dexmedetomidine possesses several desirable properties including exhibiting an opioid analgesic and anesthetic sparing effect, central sympatholytic influence, arousable sedation mimicking natural sleep, and cardiovascular stabilizing abilities. Dexmedetomidine acts on the locus coeruleus to produce dose-dependent sedation with only modest hemodynamic effect and no respiratory depression.^10–12 It is approved for procedural sedation with many off-label indications for which it is employed in perioperative medicine. It is also approved by the European Medicines Agency since 2017 for sedation and analgesia.¹ Dexmedetomidine exhibits its hypnotic effects through stimulation of central pre-and postsynaptic α2-receptors in the locus coeruleus, leading to the induction of a state of unconsciousness similar to natural sleep, with a unique phenomenon that patients remain easily rousable and cooperative. The drug is rapidly distributed and is mainly hepatically metabolized into inactive metabolites by hydroxylation and glucuronidation.^6,7 Dexmedetomidine possesses several admirable properties including its effectiveness in reducing delirium without depressing respiration. Notwithstanding, hemodynamic effects such as transient hypertension, bradycardia, and hypotension, result from its peripheral vasoconstrictive and sympatholytic properties.⁶

Application in Intensive Care

Clinical studies have shown that dexmedetomidine is suitable for both short- and long-term sedation in an intensive care setting, and is associated with a shorter time to extubation, shorter duration of mechanical ventilation, as well as patients being easier to rouse, more co-operative, and better able to communicate than those receiving midazolam or propofol.¹³ Other randomized, controlled trials also report that patients treated with dexmedetomidine are less likely to experience delirium compared to patients treated with propofol, midazolam, or remifentanil, and have more delirium- and coma-free days than patients receiving lorazepam.^13–15 It is also associated with a decrease in the length of intensive care unit stay.¹⁶ Concerning patients aged over 65 years who are admitted to the intensive care unit after non-cardiac surgery, a study observed that prophylactic low-dose dexmedetomidine significantly reduces the incidence of delirium during the first 7 days after surgery.¹⁷ In critically ill patients with septic shock, a recent clinical trial reports that on multivariable-adjusted analysis of data obtained, dexmedetomidine appeared to be associated with lower vasopressor requirements to maintain the target mean arterial pressure (MAP) compared to usual care.¹⁸ Continuous infusion of dexmedetomidine is increasingly employed for sedation in critically ill pediatric patients too,¹⁹ where its safety profile and efficacy in reducing the incidence of withdrawal syndrome during weaning from analgosedation drugs in the pediatric intensive care unit are under clinical trial investigation.²⁰

Application in Pediatrics/Children

Just as observed in adults, dexmedetomidine has shown useful in diverse areas in pediatric anesthesia where its sedative properties are useful for premedication,²¹ fiberoptic intubation,²² and radiologic procedures.²³ Its use as an adjunct for balanced anesthesia where it could decrease the use of other drugs, reduce emergence delirium, postoperative shivering, and vomiting, and exhibit neuroprotective effects.^22,24 Dexmedetomidine is an effective sedative for infants and children that only minimally depresses the respiratory system while maintaining a patent airway. Regardless, dexmedetomidine may depress the cardiovascular system, specifically, bradycardia, hypotension, and hypertension occur to varying degrees depending on the age of the child.²⁵ Overall, the safety record of dexmedetomidine suggests an effective and safe use in pediatrics/children, with appropriate monitoring and interventions to manage cardiovascular sequelae.

Route of Administration

Currently, dexmedetomidine is only approved for use in humans as intravenous medication. However, several studies have explored the practical potentials of using it through other routes. Some of the documented routes of dexmedetomidine administration that have gained traction include intrathecal, intranasal, oral, intramuscular, and inhalational (Figure 1).

Figure 1.

Routes, procedures, and pharmacological effects of dexmedetomidine. In addition to the intravenous administration of dexmedetomidine, it equally produces sufficient pharmacological outcome through other routes of administration in both surgical and procedural sedation. In its application, dexmedetomidine functions as a sedative, analgesic, adjunct anesthetic/analgesic, and anti-inflammatory agent, among other desirable effects such as bowel recovery and sore throat relief.

Intravenous

The initial approval of dexmedetomidine was for intravenous use for up to 24 hours in adults in the intensive care unit. The intravenous route of administration remains a common application route. In its general application, intravenous dexmedetomidine bolus is administered over 10 minutes (loading dose), followed by continuous infusion for maintenance (maintenance infusion) to prevent hemodynamic changes.²⁶ A decrease in heart rate up to 30% from baseline until 30 beats/min after 0.5 mcg/kg initial dose over 10 min has been reported.²⁵ In specific applications, intravenous dexmedetomidine with its stable cardio-respiratory profile, better sedation, overall patient satisfaction, and analgesia could be a valuable adjunct for intraoperative sedation during spinal anesthesia.²⁷ Approximately 55% of patients undergoing cesarean delivery under epidural or spinal anesthesia experience shivering, which may interfere with the monitoring of vital signs. Recent studies have shown that intravenous dexmedetomidine potentially helps to alleviate shivering associated with anesthesia.^28,29 One of these clinical trial studies observed that a single intravenous bolus of dexmedetomidine decreased the duration of shivering for up to 15 min during cesarean delivery under neuraxial anesthesia.²⁹ Others have observed that the administration of dexmedetomidine as a slow intravenous bolus of 15–30mg in this setting, is as or more effective than 25mg intravenous meperidine; it works within 45–90 s and the patient would rarely require a second dose. Intravenous dexmedetomidine provides an avenue for reducing shivering during cesarean delivery, limiting opioid exposure in patients, and possible replacement of drugs like meperidine.³⁰

Intrathecal

Clinical studies have evaluated the effect of intrathecal dexmedetomidine on the duration of postoperative analgesia, postoperative pain scores, and incidences of adverse events. In a systematic review and meta-analysis of randomized controlled trials, the authors concluded that intrathecal administration of dexmedetomidine prolongs postoperative analgesia duration, decreases 24-hr pain intensity, and decreases the incidence of shivering without an increase in other adverse events.³¹ Intrathecal dexmedetomidine increases the duration of the sensory blockade and analgesic effects and decreases the consumption of postoperative rescued sufentanil, an opioid analgesic associated with risks of addiction, abuse, and misuse that can lead to overdose and death.³² The analgesic role of intrathecal dexmedetomidine is promising, owing to its capability to significantly increase postoperative analgesia duration. Its application could be considered for patients undergoing surgeries with significant postoperative pain, and particularly in patients who are intolerant of systemic analgesia. Notwithstanding, the optimum dose for various surgeries and its long-term neurological impacts warrants further assessment. In a comparative study of subarachnoid anesthesia that is supplemented with either intrathecal or intravenous dexmedetomidine, it was observed that although the onset of sensory and motor block was similar in both groups, there was a longer duration in motor recovery and two-segment sensory regression in the intrathecal group. In effect, intrathecal dexmedetomidine prolongs the influence of anesthesia with arousable sedation as compared with intravenous dexmedetomidine.³³

Intranasal

Intranasal administration of dexmedetomidine produces safe and effective sedation in both adults and children. Intranasal dexmedetomidine may be given via drops from a syringe or by nasal mucosal atomization, a safe and painless way of delivering atomized medication with rapid absorption across mucosal membranes to the patient’s bloodstream.^12,34 While 1 μg.kg (−1) intranasal dexmedetomidine produces significant sedation in children aged 2–12 years, the median (95% CI) time for onset of sedation is estimated to be 25 (25–30) min and the median duration of sedation is 85 (55–100) min.³⁵ It is reported that although intravenous dexmedetomidine administration has a significantly faster onset compared to intranasal administration, there is no significant difference in sedation duration across these treatment routes. Moreover, there is no significant difference in the median onset time between intranasal routes by the atomizer and by drops.¹² Intranasal dexmedetomidine has been used successfully for sedation in children. A study that compared the two methods of intranasal dexmedetomidine delivery among 279 children reports that the successful sedation rate was 82.5% and 84.5% for atomizer and drops, respectively, with less sedation success in older children.³⁴ This implies that both modes of intranasal dexmedetomidine administration are equally effective, although increasing the age of children is linked with a reduced likelihood of successful sedation. In a similar study in pediatric patients aged 2–5 years, the researcher observed comparable onset time between both methods, with no patient requiring clinical intervene in heart rate reduction and none suffering respiratory depression after administrations of dexmedetomidine. Notwithstanding, the faces, legs, activity, cry, and consolability (FLACC) score was reduced in the mucosal atomization device group compared to the drops group, implicating nasal mucosal atomization as a better option in reducing responses to venous cannulation in pediatrics.³⁶

Oral

An oral formulation of dexmedetomidine may broaden its use and benefits in numerous care settings. A pharmacokinetic and pharmacodynamic study of oral dexmedetomidine in healthy volunteers reports that its oral administration is associated with plasma concentration-dependent decreases in heart rate and mean arterial pressure. However, only 700-mcg (but not 300 mcg or 500 mcg) reached plasma concentrations that have previously been associated with sedation.¹⁰ Another study investigated the effect of a capsule-based solid oral dosage formulation of dexmedetomidine on sleep polysomnography. In this single-site, placebo-controlled, randomized, crossover, double-blind Phase II clinical trial study, oral dexmedetomidine increased the duration of non-rapid eye movement (non-REM) stage 2 sleep by 63 min and decreased the duration of rapid eye movement (REM) sleep by 42 min.³⁷ Many studies have also compared oral dexmedetomidine with the most popular oral premedication in children, midazolam, due to the favorable clinical profile and suitability of dexmedetomidine as an alternative to midazolam. Sajid and colleagues noted that premedication with oral dexmedetomidine is as effective as oral midazolam in providing sedation and anxiolysis in children. Moreover, dexmedetomidine in addition reduces the incidence and severity of emergence agitation.³⁸ Similar observations have been documented including oral dexmedetomidine providing satisfactory sedation levels, ease of parental separation, and mask acceptance in children in a manner similar to midazolam, with children premedicated with dexmedetomidine experiencing lesser emergence delirium than those premedicated with midazolam.^39–41

Intramuscular

Dexmedetomidine has been administered to adults by intramuscular injection for perioperative anxiolysis and sedation.⁴² Several initial studies reported intramuscular route is an alternative approach to dexmedetomidine delivery for pediatric sedation and called for larger studies to evaluate the safety, efficacy, and hemodynamic outcome associated with the intramuscular dexmedetomidine in the care of patients.^42–44 Intramuscular dexmedetomidine could be applied in pediatric sedation without requiring intravenous access and has merits for electroencephalography via stimulating natural sleep pathway; however, only a limited number of studies have been documented on the efficacy of intramuscular dexmedetomidine. Recent research noted that Intramuscular dexmedetomidine exhibits a higher sedation success rate and shorter time to achieve the desired sedation level compared with oral chloral hydrate; thus, it may be an effective alternative for oral chloral hydrate in pediatric patients requiring sedation for electroencephalography.⁴⁵ Children with autism spectrum disorders requiring procedural sedation may represent a challenge for pediatricians and anesthesiologists in the emergency setting due to limited communication and poorly predictable behavioral skills. Interestingly, a case series report of children with autism spectrum disorders treated with intramuscular dexmedetomidine to perform urgent painless diagnostic procedures in various health facilities indicates that this route of administration is feasible for these special children needing urgent procedural sedation.⁴⁶ There is also evidence that dexmedetomidine premedication in low dose (1 μg·kg-1) by intramuscular route effectively induces preoperative sedation and adjuvant anesthetic effect without clinically significant bradycardia or hypotension.⁴³

Inhalational

Recent studies have examined the effects of dexmedetomidine administration through a nebulized route. For example, Misra et al evaluated the effects of preoperative dexmedetomidine nebulization on the hemodynamic response to laryngoscopy and intubation and examined the intraoperative anesthetic-analgesic requirements and recovery outcomes. The authors concluded that nebulized dexmedetomidine at 1 µg/kg attenuated the increase in heart rate but not systolic blood pressure, following laryngoscopy and reduced the intraoperative anesthetic and analgesic consumption, thus a probable alternative to the intravenous route in short duration surgeries.⁴⁷ In a similar study, nebulized dexmedetomidine was evaluated as a premedication in blunting the hemodynamic response to laryngoscopy and tracheal intubation. It was found that inhalation of the drug effectively blunted the stress response to laryngoscopy and intubation with no adverse effects.⁴⁸ These promising outcomes provide an avenue for further exploration of the inhalational administration of dexmedetomidine.

Experimental Value

Literature reports a variety of animal model studies that are linked with possible translation in clinical medicine. Key observations and clinical application value of some of these studies are summarized in Table 1. Among the many experimental models of human diseases that have shown the promising application of dexmedetomidine include lipopolysaccharide-induced acute lung injury models,^49,50 myocardial,⁵¹ lung,⁵² and intestinal⁵³ ischemia-reperfusion injury models, caeca ligation, and puncture models,^54–56 brain in vitro and in vivo models of sepsis,⁵⁷ a murine model of traumatic brain injury,⁵⁸ and spinal cord injury.⁵⁹ For instance, treatment with dexmedetomidine in experimental sepsis models reduces cytokine transcription, mortality, sepsis-associated heart injury, and inhibits inflammation, rendering it beneficial during septic conditions.⁶⁰

Table 1.

Summary of Preclinical Studies Involving Dexmedetomidine and Their Clinical Implications

Experimental Model	Key Observations	Value in Clinical Application	Reference
Cecal ligation and puncture-induced lung injury in mice	Dexmedetomidine significant decreases pro-inflammatory mediators and markers of oxidative stress in the lung tissue	Dexmedetomidine as a promising protective agent in lung injury	[56]
Spatial learning and memory in neonatal rats	Neonatal injection of dexmedetomidine (20 µg/kg) enhances spatial learning and memory.	Dexmedetomidine as a neuroprotective agent in brain injury	[70]
Hippocampal neurogenesis in mice	Dexmedetomidine attenuates ethanol-mediated hippocampal neurogenesis and reverses induced-neuroinflammation	Dexmedetomidine could reverse neurotoxicity in the developing hippocampus and deficits in hippocampal neurogenesis.	[72]
Acute lung and kidney injuries in a rat model of intra-abdominal sepsis	Dexmedetomidine attenuates sepsis-induced lung and kidney injuries and apoptosis	This calls for the need for comparative studies to determine the effects of dexmedetomidine on organ functions in early human sepsis	[55]
Rat model of cervical spinal cord injury	Dexmedetomidine improves neurological outcomes and decreases tissue damage after spinal cord injury	Dexmedetomidine as a promising inhibitor of neuroinflammation	[59]
Acute kidney injury via ischemia-reperfusion in mice	Dexmedetomidine mitigates pathohistological changes and apoptosis in the lung via α2AR/PI3K/Akt pathway	This demonstrates a novel protective mechanism against remote lung injury, hence may be a promising therapeutic avenue in remote organ cross-talk	[73]
Cecal ligation and puncture-induced liver injury in mice	Dexmedetomidine improves the survival rate of septic mice at the early stage and ameliorated the pathology of sepsis-induced liver injury	Dexmedetomidine protects against liver injury by enhancing autophagy, which alleviates inflammatory responses	[61]
Cecal ligation and puncture-induced heart injury in mice	Dexmedetomidine attenuates sepsis‑induced heme oxygenase‑1 overexpression and reduces iron concentration and ferroptosis via enhancing glutathione peroxidase 4	Promising alleviation effect in sepsis‑induced myocardial cellular injury, hence good basis for clinical studies	[62]
Cecal ligation and puncture-induced sepsis in rats	Dexmedetomidine exhibits protective effects on the myocardium by the induction of myocardial autophagy and reduction of inflammation	These observations provide the foundation for further study and may serve as the basis for innovative therapeutic strategies against septic myocardial dysfunction.	[74]
Lung ischemia-reperfusion injury in rats	Dexmedetomidine attenuates lung ischemia-reperfusion injury by activating the PI3K/Akt signaling pathway at the transcriptional level	Potential application in human ischemia-reperfusion induced lung injury	[52]
Sedation requirements in an autistic rat model	Autistic rats showed significantly longer loss of righting reflex times and shorter return of righting reflex times than controls	This outcome supports the clinical observations of increased anesthetic sedative requirements in children with autism	[75]

Abbreviations: α2AR, alpha2-noradrenergic receptor; PI3K, phosphoinositide-3-kinase.

Dexmedetomidine appears to have a protective role for the heart, liver, and spleen, as well as a beneficial role for the function of lungs and kidneys as it reduces sepsis-induced injuries and apoptosis in intra-abdominal experimental sepsis models.^61–63 Sepsis is a frequent antecedent of lung injury characterized by mitochondrial dysfunction, where the functional integrity of cells is influenced by mitochondrial dynamics. Interestingly, dexmedetomidine protects mice against cecal ligation and puncture-induced lung injury by mitigating changes in mitochondrial fusion and fission.⁵⁶ This consequently prevents changes in the wet/dry weight ratio and oxygenation index in mice, decreases markers of oxidative stress and pro-inflammatory mediators, and ameliorates altered activity of caspase-8, caspase-3, and caspase-9 enzyme in the lung tissue.⁵⁶ Moreover, dexmedetomidine prevents endotoxin-induced acute lung injury in vivo and in vitro through the preservation of mitochondrial dynamic equilibrium via the hypoxia-inducible factor (HIF)-1a/Heme oxygenase (HO)-1 signaling pathway⁶⁴ and mitigates lipopolysaccharide-induced acute lung injury by abrogating oxidative stress, mitochondrial dysfunction, and apoptosis in rats model.⁶⁵ Dexmedetomidine pretreatment in rat model of sham operation or myocardial ischemia/reperfusion, significantly attenuates ischemia/reperfusion-induced cardiac damage, as evidenced by a reduction in short-term injury indicators such as myocardial infarct size, myocardial apoptosis, cTnI release, cardiac high mobility group box protein 1 (HMGB1) expression, TNF-α, and IL-6 secretion, as well as long-term cardiac function improvement at 4 weeks after-reperfusion.⁶⁶ Other protective mechanisms of dexmedetomidine on cardiac tissue include protection through activating the PI3K/Akt signaling,⁶⁷ by down-regulating the HMGB1-TLR4-MyD88-NF-кB signaling pathway,⁶⁸ and by inhibiting inflammation and apoptosis via downregulating the endoplasmic reticulum stress signaling pathway.⁶⁹

Several experimental studies have demonstrated the neuroprotective efficacy of dexmedetomidine in many neurological and brain injury models. Zhang and colleagues investigated the effect of neonatal dexmedetomidine administration in promoting hippocampal neurogenesis and improving hippocampus-dependent spatial learning and memory under physiological conditions. Results indicated that 20 µg/kg of dexmedetomidine improves memory and spatial learning in rat pups, probably through the promotion of synaptic plasticity and hippocampal neurogenesis via stimulation of the glial cell line‐derived neurotrophic factor (GDNF)/neural cell adhesion molecule (NCAM)/cAMP response element-binding protein (CREB) signaling.⁷⁰ It is reported that a single administration of dexmedetomidine on postnatal day 7 in rats preserves hippocampal synaptic plasticity as well as synaptic transmission later in adulthood.⁷¹ Ethanol exposure within a period comparable to the third trimester in humans results in obvious neurotoxicity in the developing hippocampus and persistent deficits in hippocampal neurogenesis. In the mice model, dexmedetomidine pretreatment protects against ethanol-mediated inhibition of hippocampal neurogenesis in postnatal mice and reverses ethanol-induced neuroinflammation through repression of microglia activation and the expression of inflammatory cytokines such as TNFα, IL-6, IL-1β, and MCP-1.⁷²

Clinical Effects

As a Sedative

Dexmedetomidine is applied as a sedative in intensive care for both adults and children,¹³ in non-surgical procedures,⁴⁰ and in surgical procedures.⁷⁶ It is suitable for short- and long-term sedation, as well as light and deep sedation. Intranasal dexmedetomidine premedication is employed as a sedative to reduce stress and anxiety before general anesthesia in children. Systematic review and meta-analysis of randomized-controlled trials in children indicate that intranasal dexmedetomidine premedication provided more satisfactory sedation at parent separation, reduces the need for rescue analgesics, associated with a significantly lower incidence of nasal irritation and postoperative nausea and vomiting, as compared with other premedication treatments.⁷⁷ Emergence agitation is one of the most frequent and intractable postoperative complications among children undergoing surgery under general anesthesia. Dexmedetomidine provides ideal sedation, reducing preoperative anxiety, and facilitating smooth induction of anesthesia, hence widely used in pediatric surgery. Meta-analysis of existing data indicates that dexmedetomidine does not only prevent emergence agitation, but also relieves postoperative pain, decreases the need for rescue analgesics, and decreases postoperative nausea and vomiting events.^78–80

As an Adjunct Anesthesia/Analgesic

Dexmedetomidine has been demonstrated to function as adjunct anesthesia to enhance specific components of anesthesia, permitting lower doses of general anesthetics with fewer side effects. For instance, it has been proposed as a perineural local anesthetic adjunct to prolong peripheral nerve block duration, with new evidence indicating that it improves brachial plexus block onset, quality, and analgesia.⁸¹ Regardless, these benefits are to be weighed against elevated risks of motor block prolongation and transient bradycardia and hypotension. The favorable physiological effects combined with a limited adverse effect profile present dexmedetomidine as an attractive adjunct to anesthesia (including general and regional) for a variety of procedures in the operating room.⁴ Adjunct dexmedetomidine has been utilized to prolong local anesthetic actions and enhance effects in peripheral nerve blocks.⁸² Assessment of current evidence regarding the use of dexmedetomidine as an adjuvant to local anesthetic agents for caudal blockade anesthesia and analgesia in children indicates sufficient data to recommend its addition in patients undergoing lower extremity and infra-umbilical surgical procedures.⁸³ Besides its effects as a sedative, sympatholytic, and analgesic, dexmedetomidine has shown beneficial in its use as an adjuvant to: enhance analgesia; regulate hemodynamic response to intubation, and pneumoperitoneum and; decrease opioid-associated adverse events. A randomized controlled study reports that intraoperative dexmedetomidine infusion as adjunct analgesia is safe and effective for improving analgesia, as evident in reducing the number of patients with severe postoperative pain, postoperative consumption of morphine, and prolong time to first use of rescue analgesia.⁸⁴

As an Analgesic

Intraoperative pain management with analgesics such as remifentanil is associated with elevated postoperative analgesic requirements and opioid consumption. However, emerging evidence shows dexmedetomidine to possess characteristic properties that present it as promising analgesia during and after anesthesia. In postsurgical pain management, it has been reported to have a better pain response and hemodynamic stability than ropivacaine⁸⁵ and decreases intraoperative opioid consumption with improved postoperative sleep quality.⁸⁶ In a systematic review and meta-analysis of postoperative pain, general anesthesia including dexmedetomidine exhibited lower pain scores at rest at two (primary outcome) and 24 (secondary outcomes) postoperative hours, with less use of postoperative morphine and rescue analgesia compared to remifentanil.⁸⁷ This shows some level of evidence of intraoperative dexmedetomidine during general anesthesia to improve pain outcome during the first 24 postoperative hours compared to remifentanil. Intraoperative dexmedetomidine infusion is effective and safe for enhancing analgesia during and after elective laparoscopic cholecystectomy, where it appears to significantly decrease the number of patients with severe postoperative pain, postoperative consumption of morphine, and prolong time to first use of rescue analgesia.⁸⁴ Another study concluded that postoperative patient-controlled analgesia strategies with opioid-demedetomidine combinations reduce postoperative pain, opioid requirement, and opioid-related adverse events, implicating dexmedetomidine as a useful adjuvant to opioid-based patient-controlled analgesia.⁸⁸ However, a recent clinical trial asserted that balanced opioid-free anesthesia with dexmedetomidine, compared with remifentanil, does not produce fewer postoperative opioid-related adverse events, but rather causes a greater incidence of serious adverse events, especially bradycardia and hypoxemia.⁸⁹

As an Anti-Inflammatory Agent

Most animals have demonstrated the reduction effect of dexmedetomidine on serum and/or tissue inflammatory mediators such as TNFα, IL-6, IL-1β, NF-κB (nuclear factor kappa light chain enhancer of activated B cells), and TLR4 (toll-like receptor 4), among others.^90–92 Many of these findings have been confirmed in human studies, where dexmedetomidine is reported to reduce C-reactive protein (CRP), TNFα, IL-6, IL-1β, and alters several other mediators.^93–95 For instance, dexmedetomidine inhibits inflammatory response and reduces immunosuppression in patients undergoing multilevel spinal fusion,⁹⁵ prevents renal ischemia-reperfusion injury in part via cholinergic anti-inflammatory mechanisms,^91,96 and plays an immunomodulatory role in shifting the T-helper (Th)1/Th2 cytokine balance toward Th1 in patients with anesthetic and surgical related stress.^97,98 Dexmedetomidine exerts anti-inflammatory effects in many neurological conditions by reducing neuroinflammation. A recent study documents that dexmedetomidine upregulates microglial anti-inflammatory (M2) polarization status through inhibition of the phosphorylation of ERK1/2, resulting in enhanced anti-inflammatory effects in BV2 cells.⁹⁹ Other mechanisms associated with the anti-inflammatory effect of dexmedetomidine on microglia include reduction of the expression of microglia inflammatory (M1) marker genes such as tumor necrosis factor (TNF)-α, interleukin-1β (IL-1β), and IL-6 but improving the expression of M2 markers such as arginase-1 (Arg-1) and Flt3-interacting zinc finger protein 1 (Fizz-1),¹⁰⁰ and attenuation of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) via inhibition of extracellular signal-regulated kinase (ERK) activation in both BV2 cells and primary microglial cells.¹⁰¹ The overview of the anti-inflammatory effect of dexmedetomidine is presented in Figure 2.

Figure 2.

The anti-inflammatory effect of dexmedetomidine. Some of the specific mechanisms through which dexmedetomidine reduces inflammation include the inhibited expression of ERK1/2, IL1β, IL6, and TNF, resulting in the polarization of microglia into M2 phenotype and reducing neuroinflammation. Dexmedetomidine also regulates Th1/Th2 cells and their cytokines towards Th1 shift, which causes reduced surgical stress. Moreover, it inhibits inflammatory markers, leading to downregulated immunosuppression capable of mitigating renal injury.

Abbreviations: ERK1/2, extracellular signal-regulated protein kinases 1/2; IL, interleukin; TNF, tumor necrosis factor; Th, helper T cell; NF-кB, nuclear factor-κB; TLR4, toll-like receptor 4; CRP, C-reactive protein.

As a New Class of Sleep-Enhancing Medication

Sleep, which consists of rapid eye movement (REM) and non-REM stages 1–3 (N1-N3), is a naturally occurring state of reduced arousal that is critical for normal cardiovascular, immune, and cognitive functions. Pharmacological induction of altered arousal states that neurophysiologically approximate natural sleep, known as biomimetic sleep, might eliminate drug-induced neurocognitive dysfunction. Scientists have explored the application of dexmedetomidine as a sleep enhancer with promising outcomes.^10,37 Akeju and colleagues report that pharmacological induction of biomimetic N3 sleep with psychomotor sparing benefits is feasible, and suggest that α2a-adrenergic agonists might be developed as a new class of sleep-enhancing medications with neurocognitive sparing benefits.¹⁰² A recent systematic review showed that dexmedetomidine has advantages in improving patients’ postoperative sleep quality.¹⁰³ Other studies have also assessed the feasibility of patient-controlled sleep with dexmedetomidine in treating chronic intractable insomnia. Patient-controlled analgesia (PCA) is an “on-demand” system that allows patients to self-administer intravenous medications in small bolus doses. A PCA study concluded that patient-controlled sleep with dexmedetomidine might be a potential treatment for patients with chronic intractable insomnia; however, it is an off-label use, and the potential side effects of dexmedetomidine with long-term use needs further evaluation.¹⁰⁴

Bowel Recovery and Sore Throat-Relieving Effects

Recently, a number of studies have explored the effect of dexmedetomidine on postoperative bowel recovery parameters such as time to first bowel sounds, first faces, first flatus, or time to oral diet. A systematic review and meta-analysis of randomized controlled trials concluded that the perioperative administration of dexmedetomidine in adult patients receiving general anesthesia remarkedly shortens the time to first flatus, faces, and composite bowel recovery but does not result in a shorter time to oral diet.¹⁰⁵ In a randomized controlled trial of patients who underwent laparoscopic nephrectomy, the postoperative infusion of dexmedetomidine at 0.04 µg/kg/h facilitated bowel movements, as times to first flatus, defecation, and eating were significantly shorter.¹⁰⁶ Moreover, the combination of lidocaine and dexmedetomidine infusion significantly enhanced postoperative recovery of bowel function and pain relief in patients undergoing abdominal hysterectomy.¹⁰⁷ These findings indicate that both the postoperative and perioperative administration of the drug improves bowel recovery function, thus the need to further explore the optimum condition to maximize effect, including dosage and route.

Postoperative sore throat is an undesirable intubation-related complication after surgery. Several studies have examined the effects of dexmedetomidine in preventing this occurrence. Liu et al report that perioperative intravenous administration of dexmedetomidine has a positive effect on preventing sore throat.¹⁰⁸ Several other studies have indicated the ability of dexmedetomidine to prevent or reduce the incidence and severity intubation-related sore throat,¹⁰⁹ including intraoperative infusion,¹¹⁰ and preoperative nebulization.¹¹¹

Key Surgical Applications

Neurosurgery and Neurosurgical Procedures

Dexmedetomidine stimulates an arousable state of sedation, a beneficial effect in neurosurgical procedures that requires the patient to cooperate with procedures such as tumor surgery or implantation of deep brain stimulators. During neurosurgical procedures that require monitoring of somatosensory- and/or motor-evoked potentials, dexmedetomidine could be employed as an adjunct to general anesthesia with GABAergic drugs to reduce the dosage of the latter when these drugs impair the monitoring signals.^1,112 The use of dexmedetomidine has also been associated with neuroprotective effects and a decreased incidence of delirium, but studies confirming these effects in perioperative neurosurgical settings are lacking.

Deep brain stimulation (DBS) electrode implantation is a common treatment procedure for Parkinson’s Disease, various dystonias, medication-resistant Tourette’s syndrome, and a likely more frequent future treatment option for obsessive-compulsive disorders, depression, and obesity. The application of dexmedetomidine in DBS surgery presents more advantages over benzodiazepines and propofol.^113–116 Dexmedetomidine appears to exert only modest effects on the brain’s electrophysiological properties such as firing rates, and recording amplitudes, although these effects might be dependent on the dosage, method of administration, and location of recordings.^117,118 A review article in this area of dexmedetomidine application concluded that its use in managing conditions, including Parkinson’s disease during unilateral deep brain stimulation of the subthalamic nucleus (STN) is safe and effective and could be considered a promising option for sedation during this type of procedure.¹¹⁹

Other areas of neurological procedures that are gaining increased application of dexmedetomidine are awake craniotomy^120,121 and awake fiberoptic intubation.^122,123 The goal of awake craniotomy is to maintain adequate sedation, analgesia, respiratory, and hemodynamic stability and also to provide a cooperative patient for neurologic testing. The use of dexmedetomidine infusion with regional scalp block in patients undergoing awake craniotomy appears safe and efficacious, with the absence of major complications and higher patient satisfaction score, making it close to an ideal agent for craniotomy in an awake state.^124,125 Moreover, a combination of local anesthesia without scalp block, low-dose infusion of dexmedetomidine, propofol, and remifentanil, without the need for airways management was found to present the advantage of decreasing the dose of each drug and thus reducing the occurrence of side effects, exhibiting smooth and rapid awakenings of patients, and keeping the brain relaxed during the entire procedure.¹²⁶ Both intravenous and local application of dexmedetomidine during awake fiberoptic intubation appears promising, decreasing sudden changes in hemodynamic values and coughing, and improving patient tolerance and intubation scores.^127,128

Cardiac Surgery

The safety and efficacy of dexmedetomidine in patients who undergo cardiac surgery have been reported in several studies. In clinical studies, its application in cardiac surgery results in a reduced time of surgery and stay in intensive care units, reduced risks of abnormal hemodynamics, and improved delirium with overall good safety outcomes.² In older patients undergoing cardiac surgery, postoperative scheduled intravenous acetaminophen, combined with intravenous dexmedetomidine or propofol, reduces in-hospital delirium compared to placebo.¹²⁹ Similarly, in pediatric patients undergoing cardiac surgery, the continuous intraoperative infusions of dexmedetomidine reduce sevoflurane requirements and decrease the incidence of emergence delirium, which is associated with decreased plasma melatonin levels and surgical stress.¹³⁰ When compared with propofol, dexmedetomidine sedation reduces incidence, delays onset, and shortens the duration of postoperative delirium in patients after cardiac surgery.¹³¹ Other studies have also noted that although dexmedetomidine could decrease postoperative delirium and is associated with a shorter length of intubation after cardiac surgery, it might increase bradycardia compared to propofol.¹³² On the other hand, a 2013–2018 trial published in The Lancet reports that dexmedetomidine infusion, initiated at anesthetic induction and continued for 24 hours, did not reduce postoperative atrial arrhythmias or delirium in patients recovering from cardiac surgery.¹³³ Another clinical trial observed that the addition of low-dose-rate dexmedetomidine to a sedative regimen based on propofol does not result in a different risk of in-hospital delirium in older patients undergoing cardiac surgery, concluding that in the phase of both benefit and harm in secondary outcomes, the supplementation of postoperative propofol with dexmedetomidine is not recommended.¹³⁴ These apparent contradictions call for further clinical trial studies to establish concrete evidence on these outcomes.

Cesarean Section

Studies show that dexmedetomidine as supplements to anesthetics results in improved quality of the anesthesia and reduces the anesthetic agent requirement for cesarean section.¹³⁵ Dexmedetomidine, as an adjuvant, has been reported to prolong the duration of spinal analgesia when added to local anesthetic. Intrathecal 5μg dexmedetomidine improves the efficacy of spinal bupivacaine by 24% in patients undergoing cesarean section with spinal anesthesia, with no additional adverse event observed by adding spinal dexmedetomidine.¹³⁶ Shivering is among the common troublesome complications of spinal anesthesia and causes discomfort and discontentment in parturients undergoing cesarean sections. The administration of intrathecal dexmedetomidine is effective in lowering the intensity and incidence of shivering in women in labor undergoing cesarean sections under spinal anesthesia, without major adverse effects.¹³⁷ It is also reported that dexmedetomidine exerts protective effects on kidney injury of parturients with preeclampsia undergoing cesarean section.¹³⁸ An assessment of its effect on both the mothers and neonates during cesarean section under general anesthesia indicates that dexmedetomidine presents better neonatal Apgar scores, postoperative analgesia, and decreased catecholamine release.¹³⁹ Moreover, the use of dexmedetomidine in the perioperative period of cesarean section is not only conducive to the early conversion of infant feeding to exclusive breastfeeding but can also enhance the recovery quality and comfort of the parturient, optimize analgesia, reduce the time to the first lactation, and increase lactation.¹⁴⁰

Cancer Surgery

Surgery is considered the best curative option for several malignancies. Notwithstanding, the use of anesthesia and the surgical procedure itself are associated with immunosuppression and stress, which could contribute to immune escape of residual tumor cells and cancer recurrence.^141,142 Over the past years, researchers have been exploring concrete evidence concerning the possibility of anesthesia playing a significant role in tumor recurrence and metastasis. Just like other anesthetic agents, data from animal studies have pointed towards a potential role of dexmedetomidine in promoting cancer metastasis and recurrence when used perioperatively, especially in breast cancer surgeries, likely due to the presence of α2 adrenoreceptors in breast cancer tissue,^143–145 however, clinical evidence is lacking. To this effect, a prospective randomized controlled trial that exposed the postoperative serum of breast cancer patients who received dexmedetomidine to MCF-7 cells observed significantly elevated MCF-7 cell proliferation, migration, and invasion compared with preoperative serum.¹⁴⁴ This indicates that in patients undergoing primary breast cancer surgery, perioperative use of dexmedetomidine may influence the serum milieu in a way that encourages the malignancy of breast cancer cells.

Regardless, dexmedetomidine has shown several beneficial effects in its application in tumor surgery. Its administration provides effective cardio-cerebral protection during colorectal cancer surgery,¹⁴⁶ reduces morphine consumption, delays time to first analgesic supplementation, and decreases pain intensity postoperatively in major abdominal cancer surgery,¹⁴⁷ and attenuates immunosuppression in patients undergoing radical and reconstructive oral cancer surgery.¹⁴⁸ Dexmedetomidine could effectively decrease the expression levels of postoperative serum inflammatory factors (including TNF-α, IL-6) in patients undergoing gastric cancer surgery, enhance postoperative cognitive function by regulating the PI3K-Akt signaling pathway, and promote recovery of postoperative cognitive function.¹⁴⁹ Its application in tumor surgery in children including in abdominal malignancy¹⁵⁰ shows improved postoperative analgesia with better overall analgesia compared with other agents such as fentanyl. The surgical application and consequent effects of dexmedetomidine are summarized in Figure 3.

Figure 3.

The application of dexmedetomidine in some major surgical procedures. The figure presents a summary of desirable effects exhibited by dexmedetomidine in some selected surgical procedures.

Comparative Studies with Other Agents

The efficacy of dexmedetomidine has been compared to similar agents in several studies (Table 2). For example, an efficacy study of intrathecal dexmedetomidine and fentanyl in reducing visceral pain during an abdominal hysterectomy performed under spinal anesthesia showed better performance of dexmedetomidine as an intrathecal adjuvant. Compared to fentanyl, dexmedetomidine minimized visceral pain and prolonged postoperative analgesia.¹⁵¹ Similarly, dexmedetomidine as local anesthetics adjuvant in spinal anesthesia prolonged the duration of spinal anesthesia, improved postoperative analgesia, reduced the incidence of pruritus and did not increase the incidence of hypotension and bradycardia compared to fentanyl.¹⁵² Another report indicated that during general anesthesia for cesarean section, although remifentanil demonstrated better control of hemodynamic stability, dexmedetomidine rather demonstrated better neonatal Apgar scores, postoperative analgesia, and decreased catecholamine release.¹³⁹ However, other studies have reported no significant difference in the effect of dexmedetomidine and remifentanil on maternal hemodynamics and bi-spectral index, and neonatal outcomes in elective cesarean delivery, although remifentanil still has the potential to cause neonatal transient respiratory depression.¹⁵³

Table 2.

Comparative Studies of Dexmedetomidine and Other Drugs

Comparative Agents	Type of Study	Purpose	Outcome	Reference
Dexmedetomidine vs propofol	Meta-analysis of randomized controlled trials	Compare the effect on delirium in patients after cardiac surgery	Dexmedetomidine reduces postoperative delirium with a shorter length of intubation but might increase bradycardia after cardiac surgery compared with propofol	[132]
Midazolam alone or in combination with dexmedetomidine or clonidine	Prospective double-blind randomized study	Compare their efficacy in providing optimal intubating conditions and hemodynamic stability	Patients who receive α2 agonists are calmer, cooperative, had less pain and discomfort than midazolam. Dexmedetomidine allows better endurance, stable hemodynamics, and patent airway as compared to clonidine.	[122]
Dexmedetomidine vs fentanyl	Randomized controlled trial	Application in spinal anesthesia for abdominal hysterectomy	Dexmedetomidine performs better than fentanyl in minimizing visceral pain and prolonging post-operative analgesia.	[151]
Dexmedetomidine vs propofol	Phase I clinical trial	Study of brain functional connectivity during sleep	There is the rapid recovery of oriented responsiveness to external stimulation under dexmedetomidine sedation compared to propofol	[157]
Dexmedetomidine vs fentanyl	Systematic review and meta-analysis	Compare effects as adjuvants to local anesthetics in spinal anesthesia	Dexmedetomidine performs better by prolonging the duration of spinal anesthesia, improving postoperative analgesia, reducing the incidence of pruritus, and not increasing the incidence of hypotension and bradycardia.	[152]
Dexmedetomidine vs propofol	Randomized controlled trial	Compare the effect on delirium after cardiac surgery	Dexmedetomidine reduces incidence, delays onset, and shortens the duration of postoperative delirium	[131]
Dexmedetomidine vs remifentanil	Randomized controlled trial	Compare the effects on mothers and neonates during cesarean section under general anesthesia	Remifentanil was better in controlling hemodynamic stability, but dexmedetomidine was better in neonatal Apgar scores, postoperative analgesia, and decreasing catecholamine release	[139]
Dexmedetomidine vs remifentanil	Comparative study	Evaluate the effects on maternal and neonatal outcomes in elective cesarean delivery	Both drugs are effective to blunt hemodynamic responses to intubation and also seem safe for neonates, but remifentanil still has the potential to cause neonatal transient respiratory depression.	[153]
Dexmedetomidine vs propofol	Randomized Trial	To assess which will lower postoperative opioid analgesic consumption after total knee arthroplasty	Dexmedetomidine sedation is associated with a small but clinically important reduction in postoperative opioid use	[154]
Dexmedetomidine vs fentanyl	Randomized controlled trial	Compare as adjuvants to neuraxial anesthesia in children experiencing surgery for abdominal malignancy.	Dexmedetomidine has a better overall analgesia outcome compared to fentanyl	[150]

In patients undergoing total knee arthroplasty under spinal anesthesia, intraoperative dexmedetomidine sedation was found to be associated with a small but clinically significant reduction in postoperative opioid use compared to propofol.¹⁵⁴ The addition of dexmedetomidine and fentanyl to intrathecal bupivacaine improves postoperative analgesia following abdominal surgery for cancer in children, with better overall analgesia of dexmedetomidine compared with fentanyl.¹⁵⁰

In neurological procedures including DBS surgery, the use of dexmedetomidine has proven more advantageous over propofol and benzodiazepines. Although careful titration of the benzodiazepines or propofol might also elicit a state of anxiolysis or light sedation in which the patient remains responsive, these GABAergic medications strongly interfere with clinical signs such as tremor, even at low doses. Moreover, they impede the firing rate of neurons, leading to interference with MERs, which might raise the threshold of stimulation and interfere with macro-stimulation.^155–157 Awake fiberoptic intubation is the gold standard technique for managing patients with an anticipated difficult airway. In such situations, conscious sedation is desirable not only to make the procedure more tolerable and comfortable for the patient but also to ensure optimal intubating conditions. A study reported that patients who receive α2-adrenoceptor agonists are calmer and cooperative with less pain and discomfort during awake fiberoptic intubation than those who received midazolam. Moreover, dexmedetomidine allows stable hemodynamics, better endurance, and patent airway as compared to clonidine.¹²²

Discussion

Dexmedetomidine possesses potent sedative and anxiolytic properties and is known for its analgesic potential due to a reduction of sympathetic tone. It produces a dose-dependent effect, ranging from minimal to deep sedation. Over the past few years, the pharmacokinetic and pharmacodynamic properties of dexmedetomidine have been extensively studied within and beyond the scope of the currently approved indications, and are gaining increasing popularity and application. Current studies report its promising effects as an anti-inflammatory agent, a new class of sleep-enhancing medication, and an enhancer of bowel recovery and relief of sore throat. It has shown admirable safety and efficacy in both surgical and non-surgical procedural sedation in adults and the young. Several comparative studies involving dexmedetomidine and other agents including opioids (fentanyl, morphine, and sufentanil), α2 adrenergic agonists (clonidine), midazolam, neostigmine, magnesium sulfate, and ketamine, mostly report favorable effects of dexmedetomidine. For instance, recent reports indicate that dexmedetomidine is a promising alternative to classic sedatives for procedural sedation compared to agents such as midazolam, as it demonstrates higher patient and operator satisfaction with the patient experience of less pain, lower analgesic requirements, and easy reusability.

In the intensive care unit, sedation is meant to reduce patient discomfort, metabolic demands during organ failure, and increase tolerance towards mechanical ventilation. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill, like the one proposed by Barr and colleagues,¹⁵⁸ stipulate that the management of pain, agitation, and delirium in intensive care patients require light sedation, except for patients with acute respiratory distress syndrome or brain injury and intracranial hypertension (who rather require deep sedation). There is evidence that deep sedation in the first 48 hours after initiation of mechanical ventilation is associated with elevated long-term mortality. Interestingly, the feasibility and safety of light to mild sedation with dexmedetomidine has been demonstrated, in addition to its being a first-line drug for sedation in the intensive care unit. As compared to midazolam and propofol, dexmedetomidine is associated with a 48-hour reduction in the length of intensive care unit stay and duration of mechanical ventilation, as well as decreased incidence of delirium. Regardless of the stable hemodynamic profile produced by dexmedetomidine in both non-surgical and surgical procedures, it could also result in hemodynamic alteration-associated side effects such as hypertension or hypotension, and bradycardia owing to pre-and post-synaptic α2-receptor stimulation, which causes vasodilatation or vasoconstriction and reflex bradycardia.

Effective acute pain management has considerably evolved in recent years and is a primary area of focus in the quest to reduce the opioid epidemic. Persistent postsurgical pain has an incidence of 30–50% and negatively influences the quality of life with a significant negative burden on individuals, families, and society. Dexmedetomidine possesses analgesic properties and exhibits different pharmacological mechanisms of action when compared with opioids and other analgesics. It has been demonstrated to evoke a better pain response and hemodynamic stability compared to ropivacaine. There is also evidence of intraoperative dexmedetomidine during general anesthesia improving pain outcome during the first 24 postoperative hours compared to remifentanil. Its use during nerve blocks causes decreased postoperative pain and as an adjuvant during epidural anesthetic presents anesthetic sparing effects. Moreover, dexmedetomidine has beneficial effects of reducing intraoperative opioid consumption and enhancing postoperative sleep quality.

Postoperative cognitive dysfunction, a condition characterized by neurocognitive deficits after surgical procedures, could persist for weeks or months after the stimulating event. Like postoperative delirium, intensive care-related delirium and post-intensive care cognitive dysfunction, are likely part of the spectrum of neurocognitive defects that mostly occur after general critical illness (mostly in people with vascular disease, diabetes, atrial fibrillation, heart failure, pre-existing cognitive dysfunction, and the aged). These neurological effects plague patients with several negative outcomes including, increased length of stay at hospitals and higher mortality. Fortunately, increasing evidence indicates that dexmedetomidine can mitigate the incidence of delirium and postoperative cognitive dysfunction. While the role of neuroinflammation has been demonstrated in the pathogenesis of postoperative cognitive dysfunction, the anti-inflammatory effect of dexmedetomidine within the central nervous system has also been confirmed. However, available clinical trials appear to present conflicting evidence, in addition to the varying application of neurocognitive instruments and the differences in time endpoints used in measuring clinical outcomes. Regardless, a number of clinical trials demonstrate that dexmedetomidine reduces the incidence of postoperative delirium, a condition strongly associated with a higher occurrence of postoperative cognitive dysfunction. These preliminary pieces of evidence warrant further large-scale clinical trials to further assess the value of dexmedetomidine in this area and related conditions.

Spinal anesthesia is a standard technique for all anesthesiologists and surgeons and is commonly applied in procedures such as cesarean section and other lower body procedures. It is easy to operate, has little influence on the body’s physiological functions, permits the patient to remain awake during surgery, and excludes the risks of general anesthesia. Nonetheless, a number of adverse events including hypotension, bradycardia, shivering, nausea, and vomiting are associated with spinal anesthesia and could lead to further complications. For example, the occurrence of nausea and vomiting during operations could cause the contents of the stomach to be mistakenly inhaled into the lungs, resulting in life-threatening pneumonia. Interestingly, there is evidence of improved safety of spinal anesthesia by the use of dexmedetomidine as adjuvant anesthesia, causing the reduced incidence of these adverse events. In addition, it can shorten the onset time of local anesthesia and prolong the block duration time without increasing the drug-related side effects. In addition to dexmedetomidine, many other drugs can be administered as adjuncts for local anesthetics to enhance the efficacy and quality of spinal anesthesia. Comparative studies of dexmedetomidine and these drugs mostly indicate promising advantages of dexmedetomidine. For example, dexmedetomidine prolongs the duration of spinal anesthesia, improves postoperative analgesia, reduces the incidence of pruritus, and does not increase the incidence of hypotension and bradycardia compared to fentanyl.

Conclusion

Dexmedetomidine is a useful and attractive drug, with great potential in many clinical situations. In addition to its known primary pharmacological effects, recent studies report other effects such as a new class of sleep-enhancing medication, bowel recovery, relief of sore throat, as well as anti-inflammation. Although recent research indicates admirable advances in its clinical value and application with promising potentials, it is still limited, hence further studies are required. There is the need to explore the optimum condition, including dosage and route of administration, at which postoperative or intraoperative dexmedetomidine can exhibit maximum anti-inflammatory, bowel recovery, sleep enhancing, and sore throat relieving effects. The pharmacological effects and associated adverse events of dexmedetomidine should also be well understood by physicians and anesthesiologists before its application. Moreover, careful selection of patients and determination of the appropriate dosage are crucial steps in the application of dexmedetomidine to ensure patient safety. In the phase of the conflicting outcomes of available trials (which are mostly small-scale), there is the need for high-quality, large sample, randomized controlled trials to verify the effects and safety of dexmedetomidine.

Disclosure

The authors declare no conflicts of interest in this work.